Phase I study of bortezomib in refractory of relapsed acute leukemias

Clinical Cancer Research

Volumn 10, Issue 10, 2004, Pages 3371-3376

  Cortes, Jorge ^a   Thomas, Deborah ^a   Koller, Charles ^a   Giles, Francis ^a   Estey, Elihu ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   McConkey, David ^a   Patel, Gira ^a   Guerciolini, Roberto ^b   Wright, John ^c   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR;

ACUTE LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG INHIBITION; DRUG STRUCTURE; FATIGUE; FLUID RETENTION; HEADACHE; HUMAN; HUMAN CELL; HYPOKALEMIA; IN VITRO STUDY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SYNCOPE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; MYELODYSPLASTIC SYNDROMES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECURRENCE; TIME FACTORS;

EID: 2542481724     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0508     Document Type: Article

References (36)

1. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47.
2. Elliott P, Adams J. Recent advances in understanding proteasome function. Curr Opin Drug Discovery Dev 1999;2.
3. Chau V, Tobias JW, Bachmair A, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science (Wash DC) 1989;243:1576-83.
4. Laney JD, Hochstrasser M. Substrate targeting in the ubiquitin system. Cell 1999;97:427-30.
5. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science (Wash DC) 1996;274:1652-9.
6. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Wash DC) 1995;269:682-5.
7. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 1996;56:2649-54.
8. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 1996;14:649-83.
9. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-85.
10. Kim JY, Lee S, Hwangbo B, et al. NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochem Biophys Res Commun 2000;273:140-6.
11. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia (Baltimore) 2000;14:399-402.
12. Sovak MA, Arsura M, Zanieski G, Kavanagh KT, Sonenshein GE. The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression. Cell Growth Differ 1999;10:537-44.
13. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
14. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Investig 1997;100:2961-9.
15. Shattuck-Brandt RL, Richmond A. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 1997;57:3032-9.
16. Dokter WH, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E. The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells. Leukemia (Baltimore) 1995;9:425-32.
17. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
18. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (Wash DC) 1998;281:1680-3.
19. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (Wash DC) 1996;274:782-4.
20. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Medi Chem Lett 1998;8:333-8.
21. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Investig New Drugs 2000;18:109-21.
22. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
23. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
24. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.
25. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62:1083-6.
26. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for Phase I trials with delayed patient outcome. Stat Med 1999;18:1155-69.
27. Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
28. Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998;92:4220-9.
29. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
30. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
31. Aghajanian C, Soignet S, Dizon DS, et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
32. Estey E, Kornblau S, Pierce S, et al. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogehous leukemia. Blood 1996;88:756.
33. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-7.
34. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-40.
35. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
36. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.